TIAA CREF INVESTMENT MANAGEMENT LLC - AIMMUNE THERAPEUTICS INC ownership

AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 92 filers reported holding AIMMUNE THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is 0.28 and the average weighting 1.3%.

Quarter-by-quarter ownership
TIAA CREF INVESTMENT MANAGEMENT LLC ownership history of AIMMUNE THERAPEUTICS INC
ValueSharesWeighting
Q1 2019$1,748,000
-10.9%
78,191
-4.6%
0.00%
-50.0%
Q4 2018$1,961,000
-57.4%
81,968
-51.4%
0.00%0.0%
Q3 2018$4,598,000
+87.3%
168,514
+84.6%
0.00%0.0%
Q2 2018$2,455,000
-10.0%
91,290
+6.5%
0.00%0.0%
Q1 2018$2,729,000
-15.6%
85,730
+0.3%
0.00%0.0%
Q4 2017$3,232,000
+38.7%
85,464
-9.1%
0.00%0.0%
Q3 2017$2,330,000
+19.0%
93,985
-1.3%
0.00%
+100.0%
Q2 2017$1,958,000
+26.9%
95,247
+34.1%
0.00%0.0%
Q1 2017$1,543,000
-4.8%
71,021
-10.3%
0.00%0.0%
Q4 2016$1,620,000
+29.0%
79,218
-5.4%
0.00%0.0%
Q3 2016$1,256,000
+38.0%
83,728
-0.4%
0.00%0.0%
Q2 2016$910,000
+100.0%
84,098
+150.4%
0.00%
Q1 2016$455,000
-51.4%
33,579
-33.9%
0.00%
-100.0%
Q4 2015$937,000
+10.2%
50,789
+51.3%
0.00%0.0%
Q3 2015$850,00033,5790.00%
Other shareholders
AIMMUNE THERAPEUTICS INC shareholders Q4 2016
NameSharesValueWeighting ↓
Aisling Capital LLC 1,240,000$25,966,00057.34%
Foresite Capital Management II, LLC 2,605,499$54,559,00011.53%
Foresite Capital Management III, LLC 611,893$12,813,0004.89%
Palo Alto Investors LP 3,471,740$72,698,0004.84%
SANDERS MORRIS HARRIS LLC 486,906$10,196,0002.47%
Eventide Asset Management 3,084,000$64,579,0002.13%
Sofinnova Investments, Inc. 346,770$7,261,0000.66%
EMERALD ADVISERS, LLC 610,511$12,784,0000.60%
RICE HALL JAMES & ASSOCIATES, LLC 752,358$15,754,0000.56%
EMERALD MUTUAL FUND ADVISERS TRUST 587,464$12,301,0000.54%
View complete list of AIMMUNE THERAPEUTICS INC shareholders